Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Adults

PHASE2CompletedINTERVENTIONAL

Enrollment

4,748

Participants

Timeline

Start Date

June 14, 2016

Primary Completion Date

June 16, 2018

Study Completion Date

June 16, 2018

Conditions

Healthy Volunteers

Interventions

BIOLOGICAL

NoV Placebo-matching Saline

NoV placebo-matching saline (0.9% sodium chloride).

BIOLOGICAL

NoV GI.1/GII.4 Bivalent VLP Vaccine

NoV bivalent VLP vaccine, adjuvanted with 500 µg aluminum as Al(OH)3.

Trial Locations (1)

Great Lakes Naval Station, Great Lakes